Jim Cramer Comments On Eli Lilly (LLY)'s Shares After Pfizer CEO's Remarks

We recently published 8 Stocks Jim Cramer Discussed & Mentioned An Important Quantum Computing Development. Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer discussed.

As he discussed Amgen, it was unsurprising that weight loss drug giant Eli Lilly and Company (NYSE:LLY) also caught Cramer’s attention. Throughout 2025, the CNBC TV host has remained an ardent believer in the stock. Some of the reasons he’s cited for being optimistic about Eli Lilly and Company (NYSE:LLY) include the firm’s manufacturing investments in the US, a weight loss pill that it’s developing, and its drug portfolio excluding weight loss drugs. In this appearance, Cramer commented on Eli Lilly and Company (NYSE:LLY)’s CEO, David Ricks, and the weight loss pill:

“Look the pill is going to be, Dr. Bourla was here and he was talking about something that in three years could challenge them. All that did was make the stock go up another hundred points. Three years, Dave Ricks, I don’t think people realize, by the way, Lilly, incredibly charitable when it comes to any ailments, but, Dave Ricks is a great spokesperson for the industry.”

While we acknowledge the potential of LLY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.